{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:27:19Z","timestamp":1788193639098,"version":"build-2803163510"},"reference-count":277,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119198","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:00:53Z","timestamp":1785340853000},"page":"119198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs"],"prefix":"10.1016","volume":"318","author":[{"given":"Andr\u00e9 Berndt","family":"Penteado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Hassanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Henrique Marques","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thabata Corazza Navarro","family":"Vinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur Caminero Gomes","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa Ludmila","family":"Calil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Marques","family":"Novais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio da Silva","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-2531","authenticated-orcid":false,"given":"Gustavo Henrique Goulart","family":"Trossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119198_bib1","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1534\/genetics.114.173492","article-title":"What Do You Mean, \u201cEpigenetic\u201d","volume":"199","author":"Deans","year":"2015","journal-title":"Genetics"},{"key":"10.1016\/j.ejmech.2026.119198_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12958-020-00637-5","article-title":"Histone acetylation and the role of histone deacetylases in normal cyclic endometrium","volume":"18","author":"Gujral","year":"2020","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119198_bib3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41580-018-0074-2","article-title":"Functions and mechanisms of epigenetic inheritance in animals","volume":"19","author":"Skvortsova","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119198_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA Methylation and Its Basic Function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2026.119198_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119198_bib6","series-title":"Epigenetics Allergy Autoimmun","first-page":"3","article-title":"Epigenetics in Health and Disease","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ejmech.2026.119198_bib7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","article-title":"Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress","volume":"83","author":"Neganova","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2026.119198_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119198_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2026.119198_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41420-022-00906-9","article-title":"HDAC11 promotes both NLRP3\/caspase-1\/GSDMD and caspase-3\/GSDME pathways causing pyroptosis via ERG in vascular endothelial cells","volume":"8","author":"Yao","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.119198_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.taap.2019.03.017","article-title":"HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury","volume":"370","author":"Liu","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib13","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/ijms20102415","article-title":"p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death","volume":"20","author":"Mrakovcic","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175216","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","volume":"931","author":"Hai","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib15","first-page":"119","article-title":"Histone deacetylase (HDACs) inhibitors: Clinical applications","author":"Shanmukha","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci., Elsevier"},{"key":"10.1016\/j.ejmech.2026.119198_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/MMBR.64.2.435-459.2000","article-title":"Acetylation of Histones and Transcription-Related Factors","volume":"64","author":"Sterner","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejmech.2026.119198_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116130","article-title":"Protein lysine acetyltransferase CBP\/p300: A promising target for small molecules in cancer treatment","volume":"171","author":"Gou","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119198_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495221","article-title":"The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications","volume":"15","author":"Duan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119198_bib21","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.3390\/ijms23147664","article-title":"JmjC Family of Histone Demethylases Form Nuclear Condensates","volume":"23","author":"Vicioso-Mantis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib18","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.tibs.2020.08.004","article-title":"Controlling the Controllers: Regulation of Histone Methylation by Phosphosignalling","volume":"45","author":"Separovich","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/life12030362","article-title":"The Role of Lysine Methyltransferase SET7\/9 in Proliferation and Cell Stress Response","volume":"12","author":"Daks","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.119198_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.molcel.2013.12.005","article-title":"The Histone H3 Lysine 9 Methyltransferases G9a and GLP Regulate Polycomb Repressive Complex 2-Mediated Gene Silencing","volume":"53","author":"Mozzetta","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119198_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.ejmech.2026.119198_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1471-2148-8-294","article-title":"Evolutionary history of histone demethylase families: distinct evolutionary patterns suggest functional divergence","volume":"8","author":"Zhou","year":"2008","journal-title":"BMC Evol. Biol."},{"key":"10.1016\/j.ejmech.2026.119198_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2026.119198_bib27","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1093\/nar\/gkm432","article-title":"Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation","volume":"35","author":"Schermelleh","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147487","article-title":"Mechanisms of human DNA methylation, alteration of methylation patterns in physiological processes and oncology","volume":"875","author":"Sergeeva","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2026.119198_bib29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00018-022-04396-x","article-title":"Mechanisms that regulate the activities of TET proteins","volume":"79","author":"Joshi","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib30","series-title":"Handb. Epigenetics","first-page":"419","article-title":"Epigenetics of X-chromosome Inactivation","author":"Santos-Rebou\u00e7as","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119198_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00412-015-0525-x","article-title":"Cis- and trans-regulation in X inactivation","volume":"125","author":"Van Bemmel","year":"2016","journal-title":"Chromosoma"},{"key":"10.1016\/j.ejmech.2026.119198_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/curroncol32020088","article-title":"The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment","volume":"32","author":"Kim","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13059-025-03528-3","article-title":"The histone acetyltransferase CBP participates in regulating the DNA damage response through ATM after double-strand breaks","volume":"26","author":"Ramadan","year":"2025","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2026.119198_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113332","article-title":"Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders","volume":"216","author":"Gediya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.ejmech.2026.119198_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2026.119198_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.ejmech.2026.119198_bib38","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.3390\/ijms24054306","article-title":"Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies","volume":"24","author":"Sandon\u00e0","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2119\/molmed.2011.00116","article-title":"Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer","volume":"17","author":"Dinarello","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4161\/epi.1.1.2375","article-title":"Reactivation of Epigenetically Silenced Genes by DNA Methyltransferase Inhibitors: Basic Concepts and Clinical Applications","volume":"1","author":"Mund","year":"2006","journal-title":"Epigenetics"},{"key":"10.1016\/j.ejmech.2026.119198_bib42","series-title":"Celgene Corporation, Vidaza (azacitidine)","year":"2022"},{"key":"10.1016\/j.ejmech.2026.119198_bib43","series-title":"FDA approves azacitidine for newly diagnosed juvenile myelomonocytic leukemia","year":"2022"},{"key":"10.1016\/j.ejmech.2026.119198_bib44","series-title":"DACOGEN (decitabine)","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119198_bib45","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1135\/cccc19642060","article-title":"Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine","volume":"29","author":"P\u00edskala","year":"1964","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.119198_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF02135399","article-title":"5-Azacytidine, a new, highly effective cancerostatic","volume":"20","author":"\u0160orm","year":"1964","journal-title":"Experientia"},{"key":"10.1016\/j.ejmech.2026.119198_bib47","first-page":"405","article-title":"Biological Effects of 5-Azacytidine in Eukaryotes","volume":"30","author":"\u010cih\u00e1k","year":"1974","journal-title":"Oncology"},{"key":"10.1016\/j.ejmech.2026.119198_bib48","first-page":"339","article-title":"Effect of 5-aza-2\u2019-deoxycytidine against leukemic and hemopoietic tissues in AKR mice","volume":"15","author":"Sorm","year":"1968","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejmech.2026.119198_bib49","first-page":"123","article-title":"The activity of a new antimetabolite, 5-AZACYTIDINE, against lymphoid leukaemia in ak mice","volume":"11","author":"Sorm","year":"1964","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejmech.2026.119198_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119198_bib53","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2174\/092986708784534947","article-title":"Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias","volume":"15","author":"Leone","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib51","series-title":"5-Azacytidine\/Azacitidine","first-page":"159","author":"M\u00fcller","year":"2010"},{"key":"10.1016\/j.ejmech.2026.119198_bib52","series-title":"Small Molecules in Oncology","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119198_bib54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11684-017-0589-5","article-title":"Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses","volume":"11","author":"Wang","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1172\/JCI69739","article-title":"Clinical development of demethylating agents in hematology","volume":"124","author":"Navada","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119198_bib56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA Drug Approval Summary: Azacitidine (5-azacytidine, VidazaTM) for Injectable Suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119198_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/03602532.2018.1437446","article-title":"Effects of 5-Aza-2\u2032-deoxycytidine (decitabine) on gene expression","volume":"50","author":"Seelan","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2026.119198_bib58","series-title":"Success. Drug Discov.","first-page":"13","article-title":"Romidepsin and the Zinc\u2010Binding Thiol Family of Natural Product HDAC Inhibitors","author":"Ganesan","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119198_bib59","series-title":"The Development and Manufacture of Azacitidine, Decitabine, and Cladribine: Stereoselective Ribonucleoside Drug Synthesis Using the Vorbr\u00fcggen Glycosylation","first-page":"271","author":"Co","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119198_bib60","doi-asserted-by":"crossref","DOI":"10.1135\/cccc19642576","article-title":"Synthesis of a 2-deoxy-D-ribofuranosyl-5-azacytosine","volume":"29","author":"Pliml","year":"1964","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.119198_bib61","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119198_bib62","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119198_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119198_bib64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.ejmech.2026.119198_bib65","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib66","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib67","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib68","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","article-title":"A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases","volume":"95","author":"Richon","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib69","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1073\/pnas.93.12.5705","article-title":"Second generation hybrid polar compounds are potent inducers of transformed cell differentiation","volume":"93","author":"Richon","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib70","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A","volume":"265","author":"Yoshida","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib71","first-page":"3688","article-title":"Effects of trichostatins on differentiation of murine erythroleukemia cells","volume":"47","author":"Yoshida","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/bies.950170510","article-title":"Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function","volume":"17","author":"Yoshida","year":"1995","journal-title":"Bioessays"},{"key":"10.1016\/j.ejmech.2026.119198_bib73","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4161\/cc.25914","article-title":"Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors","volume":"12","author":"Ieran\u00f2","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.119198_bib74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","article-title":"Drug Insight: histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid","volume":"2","author":"Kelly","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib75","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12017-021-08660-4","article-title":"Repurposing Vorinostat for the Treatment of Disorders Affecting Brain","volume":"23","author":"Athira","year":"2021","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib77","doi-asserted-by":"crossref","first-page":"9110","DOI":"10.1007\/s12035-024-04115-6","article-title":"HAT and HDAC: Enzyme with Contradictory Action in Neurodegenerative Diseases","volume":"61","author":"Singh","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2026.119198_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph18040577","article-title":"Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups","volume":"18","author":"Pires","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119198_bib79","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fchem.2020.00256","article-title":"Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group","volume":"8","author":"He","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib80","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib81","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119198_bib83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-An overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119198_bib84","series-title":"Process for the preparation of vorinostat","author":"Gore","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119198_bib85","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: First Global Approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119198_bib86","series-title":"Success. Drug Discov.","first-page":"31","article-title":"The Discovery and Development of Belinostat","author":"Finn","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119198_bib87","series-title":"Pharmaceutical formulations of hdac inhibitors","author":"Bastin","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119198_bib88","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib90","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155216634178","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"23","author":"Campbell","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejmech.2026.119198_bib92","doi-asserted-by":"crossref","first-page":"30937","DOI":"10.1074\/jbc.M110.212035","article-title":"Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor \u03b2 (TGF\u03b2) Receptor II Leading to Cancer Cell Death","volume":"286","author":"Chowdhury","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib93","year":"2004","journal-title":"Belinostat"},{"key":"10.1016\/j.ejmech.2026.119198_bib94","series-title":"Novel process for the preparation of belinostat","author":"Pullagurla","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119198_bib95","author":"Watkins"},{"key":"10.1016\/j.ejmech.2026.119198_bib96","series-title":"FDA Approves Panobinostat for Some Patients with Multiple Myeloma","author":"Staff","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119198_bib97","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2017-0301","article-title":"EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119198_bib98","first-page":"296","article-title":"Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma., P T Peer-Rev. J. Formul","volume":"41","author":"Moore","year":"2016","journal-title":"Manag."},{"key":"10.1016\/j.ejmech.2026.119198_bib99","series-title":"Drug Trials Snapshot: FARYDAK (panobinostat)","year":"2020"},{"key":"10.1016\/j.ejmech.2026.119198_bib100","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat","volume":"57","author":"Van Veggel","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.119198_bib103","series-title":"Novartis, FARYDAK (panobinostat)","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119198_bib104","series-title":"Success. Drug Discov.","first-page":"59","article-title":"Discovery and Development of Farydak (NVP\u2010LBH589, Panobinostat) as an Anticancer Drug","author":"Atadja","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119198_bib105","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119198_bib106","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2146\/ajhp150487","article-title":"Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma","volume":"73","author":"Wahaib","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2026.119198_bib107","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.2147\/OTT.S87962","article-title":"Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor","author":"Redic","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.119198_bib108","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1016\/j.bmcl.2009.09.075","article-title":"Histone deacetylase and microtubules as targets for the synthesis of releasable conjugate compounds","volume":"19","author":"Passarella","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119198_bib109","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1002\/slct.202102158","article-title":"Copper\u2010Catalyzed Arylation of Olefins Using a Novel N,N\u2010Bidentate TRAM\u2010Based Ligand: Application in Synthesis of Functionalized Triarylmethanes","volume":"6","author":"Hosseini","year":"2021","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2026.119198_bib110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3184\/174751918X15357309308931","article-title":"An Improved and Efficient Synthesis of Panobinostat","volume":"42","author":"Chen","year":"2018","journal-title":"J. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib111","series-title":"Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide","author":"Bajwa","year":"2009"},{"key":"10.1016\/j.ejmech.2026.119198_bib112","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1021\/jm2003552","article-title":"Discovery of (2 E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1 H -benzimidazol-5-yl}- N -hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile","volume":"54","author":"Wang","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib82","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1021\/acs.biochem.9b00934","article-title":"Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6","volume":"58","author":"Osko","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119198_bib113","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2586.2586","article-title":"Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed\/Refractory Hodgkin Lymphoma (HL)","volume":"112","author":"Carlo-Stella","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib114","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8532","article-title":"Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed\/refractory Hodgkin's lymphoma patients","volume":"26","author":"Viviani","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejmech.2026.119198_bib116","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study","volume":"34","author":"Rambaldi","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119198_bib117","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-021-00445-z","article-title":"Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1\/2 studies and a compassionate use program","volume":"11","author":"Rambaldi","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2026.119198_bib118","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18632\/genesandcancer.117","article-title":"Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia","volume":"7","author":"Li","year":"2016","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib119","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.exphem.2012.04.007","article-title":"The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells","volume":"40","author":"Amaru Calzada","year":"2012","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.119198_bib120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00432-018-2800-8","article-title":"Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma","volume":"145","author":"Marampon","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib121","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic\u2010onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2026.119198_bib122","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2119\/molmed.2011.00030","article-title":"HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis","volume":"17","author":"Vojinovic","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib123","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1074\/jbc.M114.605428","article-title":"Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1","volume":"290","author":"Campbell","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib124","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2119\/molmed.2011.00076","article-title":"Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir","volume":"17","author":"Matalon","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib125","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.onc.1210820","article-title":"Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1\/ETO-positive cells","volume":"27","author":"Barbetti","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119198_bib126","doi-asserted-by":"crossref","first-page":"14059","DOI":"10.1073\/pnas.93.24.14059","article-title":"The AML1\/ETO fusion protein activates transcription of BCL-2","volume":"93","author":"Klampfer","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib127","article-title":"Compounds with anti-inflammatory and immunosuppressive activities","author":"Bertolini","year":"1997","journal-title":"WO1997043251A1"},{"key":"10.1016\/j.ejmech.2026.119198_bib128","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1568011043352948","article-title":"Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors","volume":"4","author":"Xie","year":"2004","journal-title":"Curr. Med. Chem.-Anti-Cancer Agents"},{"key":"10.1016\/j.ejmech.2026.119198_bib130","doi-asserted-by":"crossref","first-page":"14357","DOI":"10.1021\/acs.jmedchem.3c01422","article-title":"N -(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity","volume":"66","author":"Gerokonstantis","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4155\/fmc-2023-0122","article-title":"Key structural requirements of benzamide derivatives for histone deacetylase inhibition: design, synthesis and biological evaluation","volume":"16","author":"Cheshmazar","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib132","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib133","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib134","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells","volume":"443","author":"Gong","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119198_bib135","doi-asserted-by":"crossref","DOI":"10.2174\/1871520616666160901150427","article-title":"Preclinical and Clinical Studies of Chidamide (CS055\/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy","volume":"17","author":"Gao","year":"2017","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib136","unstructured":"D. Kobayashi, Marketing Approval of HBI-8000 (Tucidinostat) for Relapsed or Refractory ATLL Treatment in Japan, (n.d.)."},{"key":"10.1016\/j.ejmech.2026.119198_bib137","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1415597","article-title":"The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study","volume":"15","author":"Hu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119198_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1430648","article-title":"Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma","volume":"15","author":"Zong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119198_bib140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-023-01436-6","article-title":"Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK\/T-cell lymphoma to chidamide","volume":"15","author":"Chen","year":"2023","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.119198_bib141","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ijrobp.2022.04.001","article-title":"First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer\/T-Cell Lymphoma: A Randomized Phase 2 Study in China","volume":"113","author":"Chai","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib142","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11684-021-0877-y","article-title":"Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia","volume":"16","author":"Xi","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib143","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib144","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119198_bib146","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","article-title":"Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells","volume":"68","author":"Zhou","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119198_bib147","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdv227","article-title":"Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma","volume":"26","author":"Meissner","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib149","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1055\/s-0043-1768613","article-title":"Synthesis and Crystal Structure Analysis of Histone Deacetylase Inhibitor Chidamide","volume":"5","author":"Han","year":"2023","journal-title":"Pharm. Fronts"},{"key":"10.1016\/j.ejmech.2026.119198_bib148","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.bmc.2016.03.004","article-title":"Synthetic approaches to the 2014 new drugs","volume":"24","author":"Flick","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib150","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2026.119198_bib151","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib152","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib153","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib154","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1021\/acs.biochem.5b00010","article-title":"Variable Active Site Loop Conformations Accommodate the Binding of Macrocyclic Largazole Analogues to HDAC8","volume":"54","author":"Decroos","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119198_bib155","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib156","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1038\/srep04145","article-title":"The structural basis of an NADP+-independent dithiol oxidase in FK228 biosynthesis","volume":"4","author":"Li","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib157","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1136\/1\/012019","article-title":"Prediction of the three-dimensional structures of histone deacetylase 1 complexed with romidepsin and FK-A5","volume":"1136","author":"Oda","year":"2018","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.ejmech.2026.119198_bib158","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.4161\/cc.9.9.11543","article-title":"Romidepsin (FK228\/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells","volume":"9","author":"Panicker","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.119198_bib159","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib160","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1345\/aph.1R036","article-title":"Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma","volume":"46","author":"Kim","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119198_bib161","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/cas.12002","article-title":"Romidepsin (FK 228) and its analogs directly inhibit phosphatidylinositol 3\u2010kinase activity and potently induce apoptosis as histone deacetylase\/phosphatidylinositol 3\u2010kinase dual inhibitors","volume":"103","author":"Saijo","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib162","first-page":"477","article-title":"Suppression of phosphatidylinositol 3-kinase\/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells","volume":"13","author":"Kodani","year":"2005","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib163","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.biopha.2016.04.053","article-title":"Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway","volume":"82","author":"Li","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119198_bib164","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13046-021-02150-y","article-title":"Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma","volume":"40","author":"Lanzi","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib165","series-title":"Hematology","first-page":"849","article-title":"Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies","author":"Gerson","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119198_bib166","doi-asserted-by":"crossref","first-page":"9353","DOI":"10.1021\/jo801866z","article-title":"Macrolactamization versus Macrolactonization: Total Synthesis of FK228, the Depsipeptide Histone Deacetylase Inhibitor","volume":"73","author":"Wen","year":"2008","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib167","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119198_bib168","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib169","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib170","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2026.119198_bib171","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119198_bib172","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119198_bib173","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.exphem.2015.05.001","article-title":"Targeting EZH2 and PRC2 dependence as novel anticancer therapy","volume":"43","author":"Xu","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.119198_bib174","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib175","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1021\/acs.jmedchem.5b01501","article-title":"The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat","volume":"59","author":"Kuntz","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib176","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-023-01528-y","article-title":"Methylation across the central dogma in health and diseases: new therapeutic strategies","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119198_bib177","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"Yamagishi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119198_bib178","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-024-04658-4","article-title":"Pharmacology and pharmacokinetics of tazemetostat","volume":"93","author":"Orleni","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib179","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","article-title":"Valemetostat Tosilate: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119198_bib180","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-172512","article-title":"Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial","volume":"142","author":"Jacobsen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib181","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib182","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/hon.14_2879","article-title":"FIRST\u2010IN\u2010HUMAN study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS\u20103201B) in patients with relapsed or refractory NON\u2010hodgkin lymphomas","volume":"39","author":"Ishitsuka","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib183","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146772","article-title":"EZH1\/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma","volume":"138","author":"Banjo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib184","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"for collaborative Investigators, Prognosis of patients with adult T\u2010cell leukemia\/lymphoma in Japan: A nationwide hospital\u2010based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib185","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib186","unstructured":"Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia\/Lymphoma- Daiichi Sankyo US, (n.d.). https:\/\/daiichisankyo.us\/press-releases\/-\/article\/valemetostat-new-drug-application-submitted-in-japan-for-treatment-of-patients-with-adult-t-cell-leukemia-lymphoma (accessed January 15, 2026)."},{"key":"10.1016\/j.ejmech.2026.119198_bib187","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5582\/ddt.2022.01085","article-title":"Valemetostat: First approval as a dual inhibitor of EZH1\/2 to treat adult T-cell leukemia\/lymphoma","volume":"16","author":"Dou","year":"2022","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.ejmech.2026.119198_bib188","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib189","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib190","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11384","article-title":"Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance","volume":"7","author":"Brooun","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119198_bib191","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00280-025-04771-y","article-title":"Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding","volume":"95","author":"Tachibana","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib192","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpdd.1315","article-title":"Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies","volume":"13","author":"Tachibana","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2026.119198_bib193","first-page":"1641","article-title":"Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non\u2010Hodgkin lymphoma, CPT Pharmacomet","volume":"13","author":"Fukae","year":"2024","journal-title":"Syst. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib194","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/cts.13613","article-title":"Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open\u2010label, phase I study in healthy subjects","volume":"16","author":"Tachibana","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib195","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1021\/acs.jmedchem.3c02374","article-title":"Synthetic Approaches to the New Drugs Approved During 2022","volume":"67","author":"France","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib196","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.2015-0165","article-title":"Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia","volume":"20","author":"Cogle","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119198_bib197","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib198","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2014.04.010","article-title":"Comparison Between Decitabine and Azacitidine for the Treatment of Myelodysplastic Syndrome: A Meta-Analysis With 1392 Participants","volume":"15","author":"Xie","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2026.119198_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107040","article-title":"Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy","volume":"127","author":"Maurillo","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib200","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-7377","article-title":"Outcomes with azacitidine versus decitabine in AML\/MDS","volume":"146","author":"Tariq","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib201","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/cancers14061530","article-title":"The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine","volume":"14","author":"Pawlak","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119198_bib202","article-title":"Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib203","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib204","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2019001245","article-title":"Clinical developments in epigenetic-directed therapies in acute myeloid leukemia","volume":"4","author":"Pan","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2026.119198_bib205","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib206","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib207","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib208","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejmech.2026.119198_bib209","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk4423","article-title":"Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling","volume":"10","author":"Chomiak","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119198_bib210","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/77023","article-title":"DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci","volume":"25","author":"Rountree","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119198_bib211","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1101\/gad.13.15.1924","article-title":"Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation","volume":"13","author":"Zhang","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.119198_bib212","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/30764","article-title":"Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex","volume":"393","author":"Nan","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119198_bib213","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119198_bib214","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41416-018-0025-x","article-title":"DNMTi\/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells","volume":"118","author":"Bruyer","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib215","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Blagitko-Dorfs","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119198_bib216","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-02774-6","article-title":"Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics","volume":"15","author":"Tarawneh","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib217","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib218","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/cells14241997","article-title":"Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy","volume":"14","author":"Hawash","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119198_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2019.110981","article-title":"Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors","volume":"206","author":"Kenny","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119198_bib220","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1039\/C9RA02985K","article-title":"Next-generation of selective histone deacetylase inhibitors","volume":"9","author":"Yang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119198_bib221","doi-asserted-by":"crossref","first-page":"22108","DOI":"10.1039\/D2RA01969H","article-title":"Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies","volume":"12","author":"Nguyen","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119198_bib222","unstructured":"Study Details | NCT02654990 | Panobinostat\/Bortezomib\/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma | ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT02654990 (accessed June 23, 2026)."},{"key":"10.1016\/j.ejmech.2026.119198_bib223","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/OTT.S30773","article-title":"Profile of panobinostat and its potential for treatment in solid tumors: an update","author":"Anne","year":"2013","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.119198_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: A perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lddd.2025.100165","article-title":"Structural classification of HDAC inhibitors and cancer treatment prospects: A review","volume":"22","author":"Ji","year":"2025","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2026.119198_bib226","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk\u2010stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.119198_bib227","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1074\/jbc.M114.618454","article-title":"Specific Inhibition of Histone Deacetylase 8 Reduces Gene Expression and Production of Proinflammatory Cytokines in Vitro and in Vivo","volume":"290","author":"Li","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib228","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/molecules31101650","article-title":"Zinc Affinity of Benzamide-Based Histone Deacetylase Inhibitors: A DFT Study","volume":"31","author":"Toshev","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119198_bib229","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.3390\/molecules26175151","article-title":"Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases","volume":"26","author":"Fr\u00fchauf","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119198_bib230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119198_bib231","first-page":"757","article-title":"Medicinal chemistry advances in targeting class I histone deacetylases, Explor. Target","author":"Abdallah","year":"2023","journal-title":"Anti-Tumor Ther."},{"key":"10.1016\/j.ejmech.2026.119198_bib232","article-title":"Balancing Histone Deacetylase (HDAC) Inhibition and Drug\u2010likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors","volume":"17","author":"Sch\u00e4ker\u2010H\u00fcbner","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119198_bib233","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.apsb.2014.11.001","article-title":"a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94","volume":"5","author":"Zhou","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119198_bib234","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.synbio.2018.10.011","article-title":"Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228","volume":"3","author":"Liu","year":"2018","journal-title":"Synth. Syst. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119198_bib235","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108348","article-title":"Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs)","volume":"159","author":"Song","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib237","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4155\/fmc-2019-0290","article-title":"Discovery of Class I Histone Deacetylase Inhibitors Based on Romidpesin with Promising Selectivity for Cancer Cells","volume":"12","author":"Zhang","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib238","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6603464","article-title":"Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma","volume":"95","author":"O'Connor","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib239","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/ijerph13121190","article-title":"Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats","volume":"13","author":"Zhang","year":"2016","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejmech.2026.119198_bib240","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-017-01690-2","article-title":"Critical role of the HDAC6\u2013cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect","volume":"8","author":"Messaoudi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119198_bib241","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor\u2013induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119198_bib242","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/toxsci\/kfw104","article-title":"Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms","volume":"153","author":"Spence","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib243","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119198_bib244","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000492840","article-title":"Inhibition of Histone Deacetylases Induces K+ Channel Remodeling and Action Potential Prolongation in HL-1 Atrial Cardiomyocytes","volume":"49","author":"Lugenbiel","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2026.119198_bib245","doi-asserted-by":"crossref","DOI":"10.1161\/01.RES.0000079028.31393.15","article-title":"Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG","volume":"92","author":"Ficker","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib246","author":"Kazansky"},{"key":"10.1016\/j.ejmech.2026.119198_bib247","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111740","article-title":"Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials","volume":"25","author":"Rossi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib248","author":"Gramatica"},{"key":"10.1016\/j.ejmech.2026.119198_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115638","article-title":"Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment","volume":"224","author":"Maietta","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119198_bib250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13148-019-0758-2","article-title":"Histone methyltransferases EHMT1 and EHMT2 (GLP\/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"11","author":"Watson","year":"2019","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.119198_bib251","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1038\/s41598-018-27175-w","article-title":"An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors","volume":"8","author":"Bratkowski","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib252","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41467-020-20775-z","article-title":"Structures of monomeric and dimeric PRC2:EZH1 reveal flexible modules involved in chromatin compaction","volume":"12","author":"Grau","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119198_bib253","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119198_bib254","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17501911.2026.2637418","article-title":"DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions","volume":"18","author":"Michael","year":"2026","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2026.119198_bib255","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.70197","article-title":"DNA methyltransferase inhibitors in hematological malignancies and solid tumors","volume":"158","author":"Wenger","year":"2026","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib256","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41375-025-02670-y","article-title":"5-Azacytidine and decitabine induce C > G transversions in both murine and human cells","volume":"39","author":"Bertoli","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119198_bib257","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11912-021-01076-0","article-title":"Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches\u2014Focus on EZH2-Targeted Drugs","volume":"23","author":"Longley","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib258","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1467602","article-title":"Targeting extracellular matrix stiffness for cancer therapy","volume":"15","author":"Feng","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119198_bib259","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s43556-023-00126-2","article-title":"Epigenetic regulation and therapeutic targets in the tumor microenvironment","volume":"4","author":"Xie","year":"2023","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejmech.2026.119198_bib260","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejmech.2026.119198_bib261","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.ejmech.2026.119198_bib262","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1038\/s41598-017-04406-0","article-title":"Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119198_bib263","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cellsig.2018.08.011","article-title":"The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo\/YAP pathway upstream effector, in breast cancer epithelial cells, Cell","volume":"51","author":"Liu","year":"2018","journal-title":"Signal"},{"key":"10.1016\/j.ejmech.2026.119198_bib264","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13046-025-03294-x","article-title":"Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition","volume":"44","author":"Jakobsen","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13148-022-01419-z","article-title":"Drugging the epigenome in the age of precision medicine","volume":"15","author":"Feehley","year":"2023","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.119198_bib266","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1021\/acs.jmedchem.1c00787","article-title":"From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD)","volume":"64","author":"Vaidergorn","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119198_bib267","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cncr.33590","article-title":"A phase 1 study of the pan\u2010bromodomain and extraterminal inhibitor mivebresib (ABBV\u2010075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib268","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7030","article-title":"Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory acute myeloid leukemia","volume":"37","author":"Odenike","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib269","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119198_bib270","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119198_bib271","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2023.2300710","article-title":"Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies","volume":"65","author":"Stein","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2026.119198_bib272","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","article-title":"Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed\/Refractory Myeloid Malignancies","volume":"29","author":"Senapati","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119198_bib273","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119198_bib274","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3390\/molecules28031217","article-title":"PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities","volume":"28","author":"Liu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119198_bib275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.59249\/GVNM8843","article-title":"Nanotechnology-driven Epigenetic Cancer Therapy: Precision Deliveryand Sustained Release of DNA Methylation Modulators","volume":"98","author":"Ahmad","year":"2025","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119198_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.170485","article-title":"Engineered nanotechnology for epigenetic therapy in cancer treatment","volume":"525","author":"Li","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejmech.2026.119198_bib277","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.leu.2404860","article-title":"The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells","volume":"21","author":"Golay","year":"2007","journal-title":"Leukemia"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:17:35Z","timestamp":1788049055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":277,"alternative-id":["S0223523426006434"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119198","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119198"}}